Elan restructures Tysabri collaboration with Biogen in $3.25bn deal
Biogen has agreed with Elan Corporation to take over the ownership of their multiple sclerosis drug Tysabri for $3.25bn. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 7, 2013 Category: Pharmaceuticals Source Type: news
Biogen's purchase of MS drug ends rocky partnership with Elan
BOSTON (Reuters) - Biogen Idec Inc's agreement to buy Elan Corp Plc's interest in the multiple sclerosis drug Tysabri gives Biogen full control of a product that is poised for further growth and ends a long partnership that has often been contentious. (Source: Reuters: Health)
Source: Reuters: Health - February 6, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Biogen to buy Elan’s stake in MS drug
US biotechnology company will pay $3.25bn in cash and will have full control of the treatment, Tysabri, which it developed with Elan (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 6, 2013 Category: Pharmaceuticals Source Type: news
Biogen to Buy Control of MS Drug
Biogen Idec agreed to buy partner Elan's interest in Tysabri for $3.25 billion, giving it full control of the blockbuster multiple-sclerosis drug. (Source: WSJ.com: Health)
Source: WSJ.com: Health - February 6, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news
Elan Announces Restructuring of Tysabri Collaboration with Biogen Idec
Migrate From The Current 50:50
Business Collaboration To A New Structure
Upfront Payment Of $3.25 Billion
Plus Double Digit Tiered Royalty For Complete Asset
Tax Efficient Transaction
Simplified Structure Enables
Improved Alignment Of Therapy To... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 6, 2013 Category: Pharmaceuticals Source Type: news
Biogen Idec to Acquire Full Rights and Control of TYSABRI(R) from Elan for Upfront Cash and Contingent Payments
Biogen Idec gains all marketing, distribution and governance rights to TYSABRI in exchange for an upfront payment of $3.25Bn plus tiered contingent payments based on future TYSABRI worldwide sales
Terminates TYSABRI collaboration agreement and eliminate... Biopharmaceuticals, Neurology, AcquisitionsBiogen Idec, Elan Corp, TYSABRI, natalizumab, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 6, 2013 Category: Pharmaceuticals Source Type: news
Biogen Idec to Acquire Full Rights and Control of TYSABRI from Elan for Upfront Cash and Contingent Payments
-- Biogen Idec gains all marketing, distribution and
governance rights to TYSABRI in exchange for an upfront payment of
$3.25Bn plus tiered contingent payments based on future TYSABRI
worldwide sales --
-- Terminates TYSABRI collaboration... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 6, 2013 Category: Pharmaceuticals Source Type: news
Biogen pays Elan $3.25 billion to take over MS drug
DUBLIN (Reuters) - Biogen Idec is to take full ownership of blockbuster multiple sclerosis drug Tysabri after agreeing to pay Irish partner Elan $3.25 billion plus future royalties on sales of the drug. (Source: Reuters: Health)
Source: Reuters: Health - February 6, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Biogen Idec To Acquire Full Rights And Control Of TYSABRI® From Elan For Upfront Cash And Contingent Payments
Biogen Idec Inc. (NASDAQ: BIIB) today announced the company has agreed to purchase Elan’s interest in TYSABRI (natalizumab) and upon closing will gain full strategic, commercial and decision-making rights to TYSABRI. Upon the closing of the transaction, the previous collaboration agreement between the companies, whereby worldwide TYSABRI profits were split 50/50, will be terminated along with the agreement’s change of control provisions. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 6, 2013 Category: Pharmaceuticals Source Type: news
FDA, EMA Consider Natalizumab as First Line in MSFDA, EMA Consider Natalizumab as First Line in MS
Biogen Idec and Elan announced they have submitted applications in the United States and Europe for an expanded indication for natalizumab as first-line therapy for anti-JCV antibody-negative MS. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 24, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Case review: Lessons learned from fatal Progressive Multifocal Leukoencephalopathy (PML) in a patient with MS treated with natalizumab
Source: JAMA Neurology
Area: News
JAMA Neurology has featured a review on the management of a patient suspected of developing progressive multifocal leukoencephalopathy (PML) whilst on natalizumab for multiple clerosis.
The review is based on a case report of a patient who died of PML after receiving 45 infusions of natalizumab. Please see link for details.
The authors conclude that "the risks and benefits of natalizumab must be reassessed with continued therapy duration. When there is high clinical suspicion for PML in the setting of negative test results, close clinical vigilance is indicated, nata...
Source: NeLM - News - January 22, 2013 Category: Drugs & Pharmacology Source Type: news
Horizon scanning:Natalizumab (Tysabri) filed for approval in EU and US for first-line use in multiple sclerosis
Source: Reuters Health News
Area: News
Natalizumab (Tysabri) has been filed for approval in the EU and US for the first-line treatment of relapsing multiple sclerosis in patients who have tested negative for antibodies to the JC virus.
Use of this drug has been restricted due to its association with progressive multifocal leukoencephalopathy (PML), which is caused by the JC virus. There is now a test for the virus to predict if patients are at risk of developing PML, which Biogen and Elan hope will open the possibility that natalizumab could be used more widely and at an earlier stage of treatment. (Source: NeLM - News)
Source: NeLM - News - January 17, 2013 Category: Drugs & Pharmacology Source Type: news
Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in Anti-JCV Antibody Negative Patients with MS
Marketing Applications Supported by Risk Stratification Data
WESTON, Mass. & DUBLIN--(Healthcare Sales & Marketing Network)--Today Biogen Idec (BIIB) and Elan Corporation, plc (ELN) announced that they have submitted applications to the U.S. Food and Dr... Biopharmaceuticals, NeurologyElan Corp, Biogen Idec, TYSABRI, natalizumab, multiple sclerosis, JC virus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2013 Category: Pharmaceuticals Source Type: news
Biogen, Elan seek okay for first-line Tysabri use in MS
LONDON (Reuters) - Biogen Idec and Elan have filed for approval to sell their drug Tysabri as a first-line treatment for multiple sclerosis, a move that could boost sales of the drug. (Source: Reuters: Health)
Source: Reuters: Health - January 16, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Application for Tysabri as first line treatment
Biogen and Elan, the manufacturers of natalizumab (Tysabri), have applied to the EMA (for Europe) and FDA (for America) to expand the licence for the drug to include people with relapsing remitting MS who do not have antibodies to the JC virus.
Biogen press release
Natalizumab (Tysabri) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - January 16, 2013 Category: Neurology Source Type: news
